Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada.
Feng TianSherilyn K D HouleMhd Wasem AlsabbaghWilliam W L WongPublished in: PharmacoEconomics (2020)
Our analysis suggests that TAF is not cost effective at its current cost. A 33.4% reduction in price would be required to make it cost effective for HBeAg-positive patients with a Can$50,000 willingness-to-pay threshold.